New insights into targeting KRAS G12C mutations in NSCLC
Data from two studies improve knowledge of how to treat patients with a disease harbouring this molecular alteration and how to monitor response to treatment
Second-line atezolizumab plus cabozantinib fails to improve overall survival in metastatic NSCLC
Final OS analysis of the phase III CONTACT-01 trial reports negative results for immunotherapy versus docetaxel in patients progressing on checkpoint inhibitors plus chemotherapy
Long-term event-free survival benefits of neoadjuvant nivolumab plus chemotherapy for resectable NSCLC
Additional exploratory analyses of the phase III CheckMate 816 trial reveal that event-free survival at 3 years is not influenced by surgical parameters and suggest that tumour inflammation may be a useful predictive biomarker
Amivantamab efficacy in pretreated NSCLC with EGFR Exon 20 insertion mutations persists long term
Updated results from the CHRYSALIS trial also suggest a number of biomarkers predictive of sustained clinical benefit with the EGFR–MET bispecific antibody
Sotorasib improved QoL versus docetaxel in previously treated KRAS G12C-mutated NSCLC
Patients consider side-effects of the KRAS G12C inhibitor to be more tolerable and to have less interference on their lives than those due to docetaxel
Clean air is essential to prevent lung cancer
ESMO is contributing to making European Union legislation stricter on exposure limits for air pollution and asbestos to prevent new lung cancer cases
Mesothelioma treatment: from hopeless to hopeful
Recipient of the Heine H. Hansen Award 2023, Prof. Paul Baas charts the course of mesothelioma treatment over the last 30 years and warns that progress has been made only in some areas of the world
First-line immunotherapy prolongs survival in advanced or recurrent endometrial cancer
Results from the RUBY trial show improvements both in progression-free survival and overall survival in patients treated with dostarlimab plus standard chemotherapy, indicating a new standard of care
Promising advances in the molecular landscape of NETs
Molecular genetic analyses of NETs hint at actionable therapeutic targets and potential predictive biomarkers of response to axitinib
Molecular characterisation of Ewing sarcomas could provide new treatment options for a patient subset
Activating EZH2 mutations may define a new subset of aggressive Ewing sarcomas that benefit from treatment with an EZH2 inhibitor